DaVita Receives Civil Complaint

Aug 31, 2007, 01:00 ET from DaVita Inc.

    EL SEGUNDO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- DaVita Inc.
 (NYSE:   DVA), today announced it received a copy of a civil complaint filed
 in U.S. District Court for the Central District of California by plaintiff
 Sheet Metal Workers National Health Fund. The complaint names as defendants
 Amgen, Inc., Fresenius Medical Care Holdings, Inc. and DaVita Inc. The
 complaint, which has not yet been served on DaVita, is styled as a request
 for class action and alleges claims against DaVita relating to the
 administration and use of Epogen(R). The complaint's principal allegations
 against DaVita are that Epogen(R) was administered to hemodialysis patients
 intravenously, as opposed to subcutaneously, and that Epogen(R) was
     (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)
     DaVita administers Epogen(R) only pursuant to a physician's order, and
 the physician determines both the dosage amount and route of administration
 of Epogen(R). Also, the FDA-approved package insert for Epogen(R)
 recommends that Epogen(R) be administered intravenously for patients on
 hemodialysis. DaVita intends to vigorously defend the plaintiffs' claims
 and allegations contained in the complaint.
     DaVita is a leading provider of dialysis services for patients
 suffering from chronic kidney failure. DaVita operates and provides
 administrative services to approximately 1,300 outpatient dialysis centers
 located in 42 states and the District of Columbia, serving approximately
 104,000 patients.

SOURCE DaVita Inc.